Comparison of Growth Factor Releases and Degradation Rates of Membranes Obtained From A-PRF+, L-PRF, and Alb-PRF (PRF)
研究概览
地位
详细说明
Platelet-rich fibrin products have become increasingly popular in regenerative medicine because they provide a fibrin scaffold capable of releasing multiple growth factors over time. However, differences in centrifugation protocols and preparation techniques may significantly affect their biological properties.
Albumin-PRF is a recently introduced modification that combines heat-denatured plasma proteins with injectable PRF to increase scaffold stability and prolong growth factor release.
This study will compare Alb-PRF, A-PRF+, and L-PRF prepared from the same healthy volunteers. Cumulative release of VEGF, PDGF-BB, and TGF-β1 will be evaluated on Days 1, 3, 5, and 7 using ELISA. Resistance to enzymatic degradation will be assessed by measuring delta D-dimer concentrations following trypsin-EDTA exposure. The results are expected to improve understanding of the biological performance of different PRF formulations.
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
İzmir
-
Izmir、İzmir、土耳其(türkiye)、35620
- Izmir Katip Celebi University Faculty of Dentistry
-
-
参与标准
资格标准
适合学习的年龄
- 成人
接受健康志愿者
描述
Inclusion Criteria:
- Healthy volunteers aged 18 to 40 years
- Male or female
- Able and willing to provide written informed consent
- Non-smokers
- No history of systemic disease
- No regular medication use
- No use of antibiotics, corticosteroids, or non-steroidal anti-inflammatory drugs within the previous 6 months
Exclusion Criteria:
- Age younger than 18 years or older than 40 years
- Smoking
- Pregnancy or breastfeeding
- History of any systemic disease
- Regular medication use
- Use of antibiotics, corticosteroids, or non-steroidal anti-inflammatory drugs within the previous 6 months
- Refusal or inability to provide written informed consent
学习计划
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:非随机化
- 介入模型:交叉作业
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Albumin-Platelet Rich Fibrin (Alb-PRF)
Blood samples obtained from healthy volunteers were processed using the Albumin-Platelet Rich Fibrin (Alb-PRF) protocol.
Growth factor release and resistance to enzymatic degradation were evaluated under standardized laboratory conditions.
|
Autologous Albumin-Platelet Rich Fibrin prepared from peripheral venous blood using the Alb-PRF protocol for evaluation of growth factor release and enzymatic degradation.
|
|
实验性的:Leukocyte-Platelet Rich Fibrin (L-PRF)
Blood samples obtained from healthy volunteers were processed using the Leukocyte-Platelet Rich Fibrin (L-PRF) protocol.
Growth factor release (VEGF, PDGF-BB, and TGF-β1) and resistance to enzymatic degradation were evaluated under standardized laboratory conditions and compared with Albumin-PRF (Alb-PRF) and Advanced Platelet-Rich Fibrin+ (A-PRF+).
|
Autologous Leukocyte-Platelet Rich Fibrin prepared from peripheral venous blood using the L-PRF protocol for evaluation of growth factor release and enzymatic degradation.
|
|
实验性的:Advanced - Platelet Rich Fibrin+ (A-PRF+)
Blood samples obtained from healthy volunteers were processed using the Advanced Platelet-Rich Fibrin+ (A-PRF+) protocol.
Growth factor release (VEGF, PDGF-BB, and TGF-β1) and resistance to enzymatic degradation were evaluated under standardized laboratory conditions and compared with Albumin-PRF (Alb-PRF) and Leukocyte-Platelet Rich Fibrin (L-PRF) .
|
Autologous Advanced Platelet-Rich Fibrin+ prepared from peripheral venous blood using the A-PRF+ protocol for evaluation of growth factor release and enzymatic degradation.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
VEGF concentration released from PRF membranes
大体时间:Day 1, Day 3, Day 5, and Day 7
|
Quantitative assessment of VEGF released from Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) using enzyme-linked immunosorbent assay (ELISA).
|
Day 1, Day 3, Day 5, and Day 7
|
|
PDGF concentration released from PRF membranes
大体时间:Day 1, Day 3, Day 5, and Day 7
|
Quantitative assessment of PDGF released from Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) using enzyme-linked immunosorbent assay (ELISA).
|
Day 1, Day 3, Day 5, and Day 7
|
|
TGF-B concentration released from PRF membranes
大体时间:Day 1, Day 3, Day 5, and Day 7
|
Quantitative assessment of TGF-B released from Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) using enzyme-linked immunosorbent assay (ELISA).
|
Day 1, Day 3, Day 5, and Day 7
|
|
Resistance to enzymatic degradation
大体时间:60 minutes and 120 minutes
|
Assessment of fibrin degradation by measuring D-dimer levels after enzymatic digestion of PRF preparations.
|
60 minutes and 120 minutes
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.